Technical Analysis for VRX - Valeant Pharmaceuticals International, Inc.
|Grade||Last Price||% Change||Price Change|
VRX closed up 3.44 percent on Wednesday, November 22, 2017, on 1.62 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical VRX trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 20||Stochastic Reached Overbought||Other||6.23%|
|Nov 16||NR7||Range Contraction||15.34%|
|Nov 16||NR7-2||Range Contraction||15.34%|
|Nov 16||Narrow Range Bar||Range Contraction||15.34%|
|Nov 15||NR7||Range Contraction||14.46%|
|Nov 15||1,2,3 Pullback Bullish||Bullish Swing Setup||14.46%|
|Nov 15||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||14.46%|
|Nov 15||Calm After Storm||Range Contraction||14.46%|
|Nov 14||Calm After Storm||Range Contraction||15.83%|
|Nov 13||Upper Bollinger Band Walk||Other||13.29%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. It offers dermatology products, such as Zovirax Ointment, Xerese, Retin-A Micro, Elidel, Carac, Acanya gel, Sculptra and Sculptra Aesthetic, Atralin, Solodyn, Zyclara, Ziana, Vanos, Restylane family of products, and Dysport; over-the-counter (OTC) products, including CeraVe and AcneFree; dentistry products, such as Arestin and Teeth Whitening System; ophthalmology products, including Timoptic, Timoptic, Macugen, and Visudyne; and neurology and other products, such as Wellbutrin XL and Xenazine in the United States. The company also provides pharmaceutical products, including Tiazac XC, Wellbutrin XL, Zovirax, Benzaclin, and Penlac; and Cold-FX, an OTC product in Canada, as well as Duromine/Metermine, Difflam, Duro-Tuss, and Rikodeine in Australia. In addition, it offers a range of treatments, including antibiotics, treatments for cardiovascular and neurological diseases, dermatological products, and diabetic therapies, as well as a range of various OTC products in Europe; and products for a range of therapeutic classes, including vitamin deficiency, antibacterials, and dermatology in Mexico and Brazil. Further, the company provides Duromine, Andolex, and Pholtex products in South Africa; and Difflam, Duro-Tuss, Tambocor, and Norgesic in Asia. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more VRX news...
|52 Week High||18.25|
|52 Week Low||8.31|
|200-Day Moving Average||13.4703|
|50-Day Moving Average||13.6607|
|20-Day Moving Average||13.6415|
|10-Day Moving Average||15.119|
|Average True Range||0.7256|
|Chandelier Exit (Long, 3 ATRs )||14.7032|
|Chandelier Exit (Short, 3 ATRs )||13.1168|
|Upper Bollinger Band||17.2056|
|Lower Bollinger Band||10.0774|
|Percent B (%b)||0.91|
|MACD Signal Line||0.4083|
|Market Cap||5.77 Billion|
|Num Shares||349 Million|
|Price-to-Earnings (P/E) Ratio||-5.06|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||17.86|
|Resistance 3 (R3)||17.83||17.35||17.64|
|Resistance 2 (R2)||17.35||17.02||17.37||17.57|
|Resistance 1 (R1)||16.95||16.81||17.15||16.98||17.49|
|Support 1 (S1)||16.07||16.14||16.27||16.10||15.59|
|Support 2 (S2)||15.59||15.93||15.61||15.51|
|Support 3 (S3)||15.19||15.59||15.44|
|Support 4 (S4)||15.22|